LENZ CEO buys 28,089 shares in open market

LENZ Therapeutics director and CEO Evert B. Schimmelpennink made an open-market purchase of 28,089 shares of Common Stock.

Rhea-AI Filing Summary

LENZ Therapeutics director and CEO Evert B. Schimmelpennink made an open-market purchase of 28,089 shares of Common Stock. The shares were bought on March 27, 2026 at a weighted average price of $8.9505 per share, within a price range of $8.80 to $9.25. Following this transaction, he directly owns 77,289 shares of LENZ Therapeutics Common Stock.

Insider Trade Summary

Net Buyer: 28,089 shares

Net Buy 1 txn

Insider Schimmelpennink Evert B.

Role President, CEO and Secretary

Bought 28,089 shs ($251K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	28,089	$8.9505	$251K

Holdings After Transaction: Common Stock — 77,289 shares (Direct)

Footnotes (1)

1. F1. Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LENZ (LENZ) report for Evert B. Schimmelpennink?

LENZ Therapeutics reported that Evert B. Schimmelpennink executed an open-market purchase of 28,089 shares of Common Stock. This buy transaction increases his direct ownership stake and reflects a personal capital commitment at recently prevailing market prices.

How many LENZ (LENZ) shares did the CEO buy and at what price?

The CEO purchased 28,089 LENZ Therapeutics Common Stock shares at a weighted average price of $8.9505 per share. According to the filing footnote, these shares were acquired within a trade price range between $8.80 and $9.25 during the same trading day.

What is Evert B. Schimmelpennink’s LENZ (LENZ) share ownership after this transaction?

After completing the open-market purchase, Evert B. Schimmelpennink directly owns 77,289 shares of LENZ Therapeutics Common Stock. This total reflects his updated direct holdings as reported in the Form 4, incorporating the 28,089 newly purchased shares.

Was the LENZ (LENZ) insider trade a market purchase or another type of transaction?

The insider activity was an open-market purchase of Common Stock, coded as “P” in the Form 4. This indicates shares were bought on the market or in a private transaction, rather than being granted, exercised from options, or transferred as a gift.

What does the weighted average price mean in the LENZ (LENZ) Form 4 filing?

The weighted average price of $8.9505 reflects multiple individual trades totaling 28,089 shares executed between $8.80 and $9.25. The insider notes readiness to provide detailed share counts at each specific price level to the SEC, issuer, or security holders upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/30/2026 - 08:46 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schimmelpennink Evert B.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		P		28,089	A	$8.9505(1)	77,289	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average share price of an aggregate total of 28,089 shares purchased in the price range of $8.80 to $9.25 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Daniel R. Chevallard, as Attorney-in-Fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)